Background: Asthma involves variable airflow limitation and persistent airway inflammation. Eosinophilic asthma, characterized by cytokine-mediated type 2 inflammation, is generally treated with inhaled corticosteroids. However, patients with severe asthma may require biologics, such as mepolizumab, which targets IL-5 and can manage uncontrolled eosinophilic asthma.
Objective: We investigated the relationship between serum mepolizumab concentrations and treatment response in patients with severe asthma.
Methods: Patients with mepolizumab-treated severe asthma were enrolled onto this prospective cohort study. Baseline assessments were conducted and repeated at 3, 6, and 12 months. Those with response were categorized on the basis of improvements in asthma control test score, lung function, and asthma exacerbations. We quantified the serum concentration of mepolizumab at 3, 6, and 12 months after treatment by liquid chromatography coupled with tandem mass spectrometry.
Results: Twenty-five adult patients aged 20 years and older with severe asthma were included in the analysis. Serum mepolizumab concentrations significantly increased at 6 and 12 months compared with those at 3 months, particularly in those with disease that responded to therapy. Furthermore, the relative change in mepolizumab concentration was significantly higher in those with response than in those with no response. Body size parameters were negatively correlated with mepolizumab concentration. In those with response, there were inverse correlations between mepolizumab concentration and baseline body size parameters.
Conclusions: The study observed a yearlong increase in mepolizumab concentrations, particularly in those with response, indicating a potential mepolizumab surplus. Correlations between mepolizumab concentrations and baseline characteristics suggested differing mepolizumab requirements between those with response and those with no response. Further research is needed to validate these findings and optimize treatment strategies for patients with severe asthma.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11836490 | PMC |
| http://dx.doi.org/10.1016/j.jacig.2025.100410 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Allergen Immunotherapy in Autoimmune Terrain: A Case Study.
Indian J Otolaryngol Head Neck Surg
January 2025
Department of Endocrinology, Joshi Clinic, Mumbai, India.
Allergen immunotherapy (AIT), or specific immunotherapy (SIT), is an effective treatment for inducing immune tolerance to specific allergens. It is widely used for allergic rhinitis, conjunctivitis, asthma, and Hymenoptera venom allergies, with recent applications to food allergies and atopic dermatitis. Despite its benefits, the use of SIT in patients with autoimmune diseases is controversial due to concerns about its potential to induce or exacerbate autoimmune conditions.
View Article and Find Full Text PDFVenous thromboembolism associated with severe dyspnea and asthma in 21,205 adults from the Danish population.
J Asthma
March 2025
Department of Clinical Biochemistry, Zealand University Hospital, Køge, Denmark.
Background: Long-term consequences after a pulmonary embolism include lung function deficits, dyspnea, and chronic thromboembolic pulmonary hypertension. Recent studies suggest patients who experience pulmonary embolism may also be at increased risk of asthma.
Methods: We tested the hypothesis that individuals with pulmonary embolism or deep vein thrombosis (venous thromboembolism) have lower lung function, or higher risks of dyspnea and asthma using data from 21,205 random adults from the Danish General Suburban Population Study.
Article Synopsis
- Asthma is a complex inflammatory disease that can be influenced by various underlying mechanisms, and this study focused on patients with both asthma and primary antibody immunodeficiency (PAD).
- Out of 33 patients studied, those with low T2 inflammatory markers showed a significant increase in blood eosinophils after receiving immunoglobulin therapy (IVIg), which is associated with better asthma management.
- The results indicate that IVIg therapy leads to a notable decrease in respiratory infections and asthma exacerbations in patients with asthma and PAD, suggesting it might help change the way asthma presents in these patients.
Heated High Flow Nasal Cannula and Bilevel Positive Airway Pressure in Pediatric Asthma Exacerbations.
J Asthma
March 2025
Department of Pediatrics, University of Rochester, Rochester, NY, U.S.A.
Objective: Heated High Flow Nasal Cannula (HHFNC) and Bilevel Positive Airway Pressure (BPAP) are non-invasive respiratory support modalities used in pediatric asthma exacerbations. We aim to examine differences in characteristics and outcomes for patients admitted to the Pediatric Intensive Care Unit (PICU) on standard therapy (ST) alone (continuous albuterol and systemic corticosteroids), ST plus HHFNC, and ST plus BPAP.
Methods: This is a retrospective and prospective observational cohort study.
Safety and effectiveness of mepolizumab in adult patients with severe asthma with an eosinophilic phenotype from India: a Phase IV, open-label, single-arm, 24-week study (PRISM).
J Asthma
March 2025
Medical Affairs, GSK, Mumbai, India.
ObjectiveExisting mepolizumab trials have excluded patients with severe asthma with an eosinophilic phenotype (SAEP) from India. This study (NCT04276233) investigated the safety and effectiveness of mepolizumab in Indian adults with SAEP.MethodsMulti-centre, open-label, single-arm, interventional study; patients received 100 mg mepolizumab subcutaneously every four weeks for 24 weeks.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!